Biomarker and specialty lab data are increasingly being incorporated in FDA submissions given the robust insights they provide on key clinical objectives, including pharmacological effects, and drug safety and effectiveness.
Jared Kohler, PhD
Advertisement
Articles by Jared Kohler, PhD
Advertisement
Latest Updated Articles
Preparing Specialty Lab Data for FDA Submission in the New Regulatory EnvironmentPublished: March 12th 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
Focusing on Site Needs and Challenges: Quick Tips for Sponsors/CROs
3
AI in Action: Breaking Down Clinical Trial Bottlenecks
4
Overcoming Recruitment and Retention Barriers in Alzheimer’s and Dementia Studies
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
